Ask AI
ProCE Banner Activity

Tomorrow’s ART, Today: Personalized Treatment for All People With HIV

Clinical Thought

Antiretroviral therapy is never one-size-fits-all. Here’s why we should always aim for an appropriately individualized regimen for each person living with HIV when initiating therapy and be open to modifying a virologically suppressive regimen if necessary.

Released: December 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Merck & Co., Inc., Rahway, NJ, USA

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who provide care for people living with HIV.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select an appropriately individualized ART regimen for each person living with HIV when initiating therapy or modifying a virologically suppressive regimen

  • Apply best practices in the individualized management of comorbidities and comedications that occur commonly among people living with HIV

  • Identify how anticipated future ART agents may provide additional options for selecting a regimen that is optimized for each individual

Disclosure

Primary Author

Tristan J. Barber, MA, MD, FRCP: consultant/advisor/speaker: Gilead, Johnson & Johnson, Merck Sharp & Dohme, Novo Nordisk, ViiV.